image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 4.21
-0.237 %
$ 534 M
Market Cap
-421.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ORGO stock under the worst case scenario is HIDDEN Compared to the current market price of 4.21 USD, Organogenesis Holdings Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ORGO stock under the base case scenario is HIDDEN Compared to the current market price of 4.21 USD, Organogenesis Holdings Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ORGO stock under the best case scenario is HIDDEN Compared to the current market price of 4.21 USD, Organogenesis Holdings Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ORGO

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
482 M REVENUE
11.29%
-1.28 M OPERATING INCOME
-10.24%
861 K NET INCOME
-82.59%
14.2 M OPERATING CASH FLOW
-54.04%
-10 M INVESTING CASH FLOW
58.82%
27.6 M FINANCING CASH FLOW
602.03%
127 M REVENUE
9.97%
10.2 M OPERATING INCOME
63.71%
7.67 M NET INCOME
-37.77%
10.9 M OPERATING CASH FLOW
25.78%
-3.36 M INVESTING CASH FLOW
-30.83%
33.6 M FINANCING CASH FLOW
2106.50%
Balance Sheet Organogenesis Holdings Inc.
image
Current Assets 286 M
Cash & Short-Term Investments 136 M
Receivables 110 M
Other Current Assets 40.5 M
Non-Current Assets 212 M
Long-Term Investments 0
PP&E 126 M
Other Non-Current Assets 85.7 M
27.23 %22.07 %8.14 %25.35 %17.21 %Total Assets$497.9m
Current Liabilities 77.5 M
Accounts Payable 28.9 M
Short-Term Debt 9.11 M
Other Current Liabilities 39.5 M
Non-Current Liabilities 35.1 M
Long-Term Debt 34.2 M
Other Non-Current Liabilities 894 K
25.68 %8.10 %35.05 %30.38 %Total Liabilities$112.6m
EFFICIENCY
Earnings Waterfall Organogenesis Holdings Inc.
image
Revenue 482 M
Cost Of Revenue 116 M
Gross Profit 366 M
Operating Expenses 368 M
Operating Income -1.28 M
Other Expenses -2.14 M
Net Income 861 K
500m500m450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)482m(116m)366m(368m)(1m)2m861kRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.99% GROSS MARGIN
75.99%
-0.27% OPERATING MARGIN
-0.27%
0.18% NET MARGIN
0.18%
0.33% ROE
0.33%
0.17% ROA
0.17%
0.09% ROIC
0.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Organogenesis Holdings Inc.
image
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 861 K
Depreciation & Amortization 17 M
Capital Expenditures -10 M
Stock-Based Compensation 10.6 M
Change in Working Capital 0
Others -3.54 M
Free Cash Flow 4.18 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Organogenesis Holdings Inc.
image
Wall Street analysts predict an average 1-year price target for ORGO of $5.5 , with forecasts ranging from a low of $5 to a high of $6 .
ORGO Lowest Price Target Wall Street Target
5 USD 18.76%
ORGO Average Price Target Wall Street Target
5.5 USD 30.64%
ORGO Highest Price Target Wall Street Target
6 USD 42.52%
Price
Max Price Target
Min Price Target
Average Price Target
77666655554444333322Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Organogenesis Holdings Inc.
image
Sold
0-3 MONTHS
128 K USD 1
3-6 MONTHS
1.36 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness Organogenesis recommends CMS also implement an integrated coverage and payment policy Organogenesis recommends CMS also implement an integrated coverage and payment policy globenewswire.com - 3 weeks ago
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. globenewswire.com - 3 weeks ago
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby. seekingalpha.com - 2 months ago
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. globenewswire.com - 2 months ago
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. globenewswire.com - 3 months ago
Organogenesis Expands Manufacturing Capacity to Support Future Growth CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. globenewswire.com - 5 months ago
Organogenesis Commends Final LCDs Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination globenewswire.com - 5 months ago
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ross Osborne - Cantor Fitzgerald Ryan Zimmerman - BTIG Operator Please stand by. Welcome ladies and gentlemen to the Third Quarter of Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode. seekingalpha.com - 5 months ago
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases globenewswire.com - 5 months ago
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA). globenewswire.com - 5 months ago
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th. globenewswire.com - 6 months ago
Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com - 6 months ago
8. Profile Summary

Organogenesis Holdings Inc. ORGO

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 534 M
Dividend Yield 0.00%
Description Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Contact 85 Dan Road, Canton, MA, 02021 https://organogenesis.com
IPO Date Jan. 5, 2017
Employees 869
Officers Mr. Brian Grow Chief Commercial Officer Mr. Robert Cavorsi Vice President of Strategy Mr. Patrick Bilbo Chief Operating Officer Ms. Lori H. Freedman B.A., Esq., J.D. Chief Administrative & Legal Officer Mr. William R. Kolb CPA Secretary Mr. David C. Francisco Chief Financial Officer Mr. Gary S. Gillheeney Sr. President, Chief Executive Officer, Chair of the Board